The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 4 briefings matching “thyroid”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

NEPHROLOGY · PRECLINICAL

Gut-targeted interventions to complement PTH-lowering therapy

These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health. Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 15, 2026

ONCOLOGY · REAL-WORLD COHORT

Global Proposal for the TNM Staging System for Poorly Differentiated Thyroid Cancer

This cohort study found that this PDTC-specific staging system provides improved prognostic stratification reflecting its different biology. These data provide a strong rationale for the potential inclusion of a stand-alone American Joint Committee on Cancer staging system for PDTC.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJAMA OncologyNov 6, 2026

GASTROENTEROLOGY · PHASE III

Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Simedeutirom led to higher rates of MASH improvement without worsening of fibrosis (tissue scarring) than placebo (inactive comparison treatment) after 52 weeks, warranting further investigation in Phase 3 trials. Simedeutirom is a selective thyroid hormone receptor-β agonist that has previously been shown to reduce hepatic fat content in metabolic dysfunction-associated steatotic liver disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyOct 16, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Hashimoto's thyroiditis: two decades on

This Review synthesises developments over the past two decades in the epidemiology, natural history, aetiopathogenesis, diagnosis, and management of Hashimoto's thyroiditis, and considers emerging mechanistic insights and approaches to precision medicine that might inform future disease-modifying therapies. Management centres on levothyroxine replacement for overt hypothyroidism, with an individualised approach to subclinical disease.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Diabetes & EndocrinologyOct 7, 2026

Interactive Fact Check